GBI Research’s latest report, The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players, provides an in-depth assessment of the current trends in the global mid-size pharma market, along with growth strategies being pursued by these companies.
The report contains an overview of mid-size pharma companies in terms of overall revenue, R&D spending, number of pipeline and marketed products, number of employees, location of headquarters, year-on-year revenue and R&D expenditure. It also includes profiles of the top mid-size companies with overall revenue forecasts, and sales forecasts for top marketed products and late-stage pipeline products up to 2023.
Pharmaceutical companies with annual revenue in 2016 of between $1 billion and $10 billion are considered to be mid-size companies in the report. The mid-size pharma market is growing rapidly. Most of these companies are focusing heavily on developing a portfolio of generic products covering a variety of therapy areas and geographies. They have been competing with large pharma by developing generic products of high value innovative biologics after their patent expiry.
Additionally, the top mid-size companies are involved in the end-to-end development of innovative products, although in these cases their focus is limited to specific therapy areas. A few mid-size companies diverge from the typical trends and are particularly focused on rare diseases. A wide range of strategies, such as mergers and acquisitions, in-house R&D, a shift towards high value generics and a focus on rare diseases, are being pursued by mid-size pharma companies to sustain and grow in the market.
This report provides key insights on the mid-size pharma industry, from data covering over 80 mid-size companies both those focused exclusively on pharma, and those also involved in other divisions of healthcare, such as medical devices, in addition to pharma products.
How can the mid-sized pharma segment be defined in general, and what is its role in the industry?
Which mid-size pharma companies are on the leaders in terms of revenue, R&D expenditure, number of R&D products, marketed products and number of employees in 2016?
What is the revenue forecast for the key mid-size companies in 2023?
What are the key marketed products of the top mid-size pharma companies? What were the global sales figures in 2016 and what are the forecasts for 2023 for these products?
Which therapy areas are the key mid-size companies are focusing on? What are the global sales forecasts of late-stage pipeline products that are set to enter the market during the forecast period?
What was the year-on-year revenue growth and year-on-year R&D expenditure of key mid-size pharma companies between 2014 and 2016?
What are the key strategies followed by mid-size pharma companies to improve their revenue and push towards joining the large pharma segment?
What are the key challenges faced by mid-size pharma companies?
Reasons to buy
Interpret the key players in the mid-size pharma segment through the analysis of companies, particularly based on R&D investments, year-on-year revenue and R&D expenditure, and pipeline and marketed products.
Gain insights on how mid-size pharma companies have explored new technologies to shape their current portfolios and R&D pipelines.
Understand the detailed profiling of top mid-size pharma companies based on their revenue in 2016. The profiling of the companies includes top-selling marketed products, major late-stage pipeline products expected to enter into the market in the near future and their forecasts, and key deals analysis.
Recognize the various challenges faced by mid-size pharma companies.
Understand the major growth strategies followed by mid-size pharma companies in recent years.
Table of Contents
Introduction What is the Mid-Sized Pharma Segment and What is its Role in the Industry? Why is Mid-size Pharma a Key Element of the Industry? Mid-size Pharma Players with Revenue Forecasts Comparative Analysis and Ranking - Based on Revenue R&D Expenditure Number of Pipeline Products Number of Marketed Products Number of Employees Location of Headquarter Year-on-Year Revenue Year-on-Year R&D Expenditure Key Points Mid-size Pharma Companies - Growth Strategies related to Deals and Collaborations Mergers and Acquisitions Licensing Agreements and Partnerships R&D Collaboration Geographical Expansion In-House Research and Development Shift towards High-Value Generics from Low-Value Generics Brand Building Specialized Therapy Areas and Rare Diseases Key Points Top Mid-size Pharma Companies Daiichi Sankyo Valeant Pharmaceuticals Eisai Regeneron Pharmaceuticals UCB Les Laboratories Servier Sun Pharmaceutical Endo International Mallinckrodt Kyowa Hakko Kirin Alexion Pharmaceuticals Taisho Pharmaceutical Overview Top Marketed Products Pipeline Overview Late stage Products with Sales Forecast Revenue Forecast Deals by Value and Volume Key Deals Top Small Pharma Companies Likely to Enter the Mid-size Segment Horizon Pharma Intas Pharmaceuticals Hypermarcas Challenges Faced by Mid-size Pharma Conclusion List of Mid-size Pharma Companies Bibliography Disclaimer
Write comment about above report:
Published By: CBR Pharma Insights
CBR Pharma Insights86
Did you find what you are/were looking for
If not, read below and browse through other relevant pages for similar market research
reports OR get in touch with us through the form/contact info in your right navigation
panel and well share relevant market report titles for you to explore.
Query failed: connection to localhost:9312 failed (errno=111, msg=Connection refused).
We are on:
500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.